In a patient with HR+ breast cancer who is not able to tolerate adjuvant AI or standard dose tamoxifen due to side effects, would you consider a lower dose of tamoxifen?

Since we don't have data on the efficacy of low dose tamoxifen for treatment of invasive cancer, this would be a last resort. The TAM01 trial showed 5mg of tamoxifen was better than placebo for preventing recurrence in women with intraepithelial lesions. Anecdotally, I have had an occasional early s...